Registration Dossier
Registration Dossier
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 265-314-4 | CAS number: 65036-46-6
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data

Acute Toxicity: oral
Administrative data
- Endpoint:
- acute toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2018
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
- Report date:
- 2018
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method)
- Version / remarks:
- OECD 423, v. 2001
EC 440/2008 B.1, v. 2008
EPA OPPTS 870.1000, EPA 712-C-02-189/190, v. 2002 - Deviations:
- no
- Principles of method if other than guideline:
- Guideline method
- GLP compliance:
- yes (incl. QA statement)
- Test type:
- acute toxic class method
- Limit test:
- yes
Test material
- Reference substance name:
- 2-[4-[(hexahydro-2,4,6-trioxo-5-pyrimidyl)azo]phenyl]-6-methylbenzothiazole-7-sulphonic acid, compound with 2,2',2''-nitrilotris[ethanol] (1:1)
- EC Number:
- 265-314-4
- EC Name:
- 2-[4-[(hexahydro-2,4,6-trioxo-5-pyrimidyl)azo]phenyl]-6-methylbenzothiazole-7-sulphonic acid, compound with 2,2',2''-nitrilotris[ethanol] (1:1)
- Cas Number:
- 65036-46-6
- Molecular formula:
- C18H13N5O6S2.C6H15NO3
- IUPAC Name:
- 2-[4-[(hexahydro-2,4,6-trioxo-5-pyrimidyl)azo]phenyl]-6-methylbenzothiazole-7-sulphonic acid, compound with 2,2',2''-nitrilotris[ethanol] (1:1)
- Test material form:
- liquid
Constituent 1
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, 97633 Sulzfeld, Germany
- Females (if applicable) nulliparous and non-pregnant: yes
- Age at study initiation: 8-10 weeks
- Weight at study initiation: Step 1: 155–162 g; Step 2: 159–177 g
- Fasting period before study: 16 to 19 hours (access to water was permitted)
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: >=5 days
ENVIRONMENTAL CONDITIONS
- Full barrier in an air-conditioned room
- Temperature: 22 +/- 3 °C
- Relative humidity: 55 +/- 10%
- Artificial light, sequence being 12 hours light, 12 hours dark
- Air change: 10 x / hour
- Free access to Altromin 1324 maintenance diet for rats and mice (lot no. 0426)
- Free access to tap water, sulphur acidified to a pH value of approximately 2.8 (drinking water, municipal residue control, microbiological controls at regular intervals)
- The animals were kept in groups in IVC cages, type III H, polysulphone cages on Altromin saw fibre bedding (lot no. 02102171114)
- Certificates of food, water and bedding are filed for two years at BSL Munich and afterwards archived at Eurofins Munich
- Adequate acclimatisation period (at least five days) under laboratory conditions
IN-LIFE DATES: From: To: 17.1.2018-14.2.2018
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- unchanged (no vehicle)
- Details on oral exposure:
- VEHICLE
None used
MAXIMUM DOSE VOLUME APPLIED:
2000mg/kg bw applied as such. Max. animal weight: 177 grams
CLASS METHOD (if applicable)
- Rationale for the selection of the starting dose: no toxicity expected based on structural analogue - Doses:
- 2000 mg/kg bw in step 1 and 2
- No. of animals per sex per dose:
- 3 f
- Control animals:
- no
- Details on study design:
- Duration of observation period following administration: 14 days
Frequency of observations and weighing: All animals were observed for 14 days after dosing for general clinical signs, morbidity and mortality. The animals were weighed on day 1 (prior to the administration) and on days 8 and 15. A careful clinical examination was made several times on the day of dosing (at least once during the first 30 minutes and with special attention given during the first 4 hours post-dose). As soon as symptoms were noticed they were recorded. Thereafter, the animals were observed for clinical signs once daily until the end of the observation period. All abnormalities were recorded. Cageside observations included changes in the skin and fur, eyes and mucous membranes. Also respiratory, circulatory, autonomic and central nervous systems and somatomotor activity and behaviour pattern were examined. Particular attention was directed to observations of tremor, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
Necropsy of survivors performed: At the end of the observation period all animals were sacrificed with an overdosage of pentobarbital injected intraperitoneally (CP-Pharma; lot no.: 17C202; expiry date: 28 February 2019) at a dosage of 250-400 mg/kg bw.
All animals were subjected to gross necropsy and examined macroscopically for gross pathological changes. In the absence of gross pathological changes no tissues were preserved for a possible histopathological evaluation. - Statistics:
- N/A
Results and discussion
Effect levels
- Key result
- Sex:
- female
- Dose descriptor:
- LD50 cut-off
- Effect level:
- 5 000 mg/kg bw
- Based on:
- test mat.
- Mortality:
- None
- Clinical signs:
- other: See table.
- Gross pathology:
- No specific gross pathological changes were recorded for any animal.
- Other findings:
- None
Any other information on results incl. tables
Step |
Animal No. / Sex |
Starting Dose (mg/kg bw) |
Timepoint |
Observations |
|||||
1 |
1 / Female |
2000 |
0 min – 15 d |
nsf |
|||||
2 / Female |
0 min – 15 d |
nsf |
|||||||
3 / Female |
0 min – 15 d |
nsf |
|||||||
2 |
4 / Female |
0 – 120 min |
nsf |
||||||
120 – 180 min |
Slight piloerection |
||||||||
180 – 240 min |
Moderate piloerection |
||||||||
240 min – 15 d |
nsf |
||||||||
5 / Female |
0 – 120 min |
nsf |
|||||||
120 – 180 min |
Slight piloerection |
||||||||
180 – 240 min |
Moderate piloerection |
||||||||
240 min – 15 d |
nsf |
||||||||
6 / Female |
0 – 120 min |
nsf |
|||||||
120 – 180 min |
Slight piloerection |
||||||||
180 – 240 min |
Moderate piloerection |
||||||||
240 min – 15 d |
nsf |
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Under the conditions of the present study, a single oral application of the test item Direct Yellow 147 to rats at a dose of 2000 mg/kg body weight was associated with slight signs of toxicity but no mortality.
The median lethal dose of Direct Yellow 147 after a single oral administration to female rats, observed over a period of 14 days is LD50 cut-off (rat): 5000 mg/kg bw - Executive summary:
Under the conditions of the present study, a single oral application of the test item Direct Yellow 147 to rats at a dose of 2000 mg/kg body weight was associated with slight signs of toxicity but no mortality.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
